143 related articles for article (PubMed ID: 15645696)
41. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H
Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524
[TBL] [Abstract][Full Text] [Related]
42. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
43. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
Roberge JN; Brubaker PL
Endocrinology; 1993 Jul; 133(1):233-40. PubMed ID: 8319572
[TBL] [Abstract][Full Text] [Related]
44. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
Hira T; Koga T; Sasaki K; Hara H
Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
[TBL] [Abstract][Full Text] [Related]
45. The enteroinsular axis in dipeptidyl peptidase IV-negative rats.
Pederson RA; Kieffer TJ; Pauly R; Kofod H; Kwong J; McIntosh CH
Metabolism; 1996 Nov; 45(11):1335-41. PubMed ID: 8931636
[TBL] [Abstract][Full Text] [Related]
46. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia.
Ahrén B; Holst JJ
Diabetes; 2001 May; 50(5):1030-8. PubMed ID: 11334405
[TBL] [Abstract][Full Text] [Related]
47. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
Matikainen N; Björnson E; Söderlund S; Borén C; Eliasson B; Pietiläinen KH; Bogl LH; Hakkarainen A; Lundbom N; Rivellese A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR
PLoS One; 2016; 11(1):e0145890. PubMed ID: 26752550
[TBL] [Abstract][Full Text] [Related]
48. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
49. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion.
Jia X; Brown JC; Ma P; Pederson RA; McIntosh CH
Am J Physiol; 1995 Apr; 268(4 Pt 1):E645-51. PubMed ID: 7733263
[TBL] [Abstract][Full Text] [Related]
50. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism.
Vahl T; D'Alessio D
Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):461-8. PubMed ID: 12806222
[TBL] [Abstract][Full Text] [Related]
51. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.
Orskov C; Wettergren A; Holst JJ
Scand J Gastroenterol; 1996 Jul; 31(7):665-70. PubMed ID: 8819215
[TBL] [Abstract][Full Text] [Related]
52. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery.
Patriti A; Facchiano E; Sanna A; Gullà N; Donini A
Obes Surg; 2004; 14(6):840-8. PubMed ID: 15318993
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity.
Ranganath LR; Beety JM; Morgan LM
Horm Metab Res; 1999 Apr; 31(4):262-6. PubMed ID: 10333081
[TBL] [Abstract][Full Text] [Related]
54. Gastric emptying and release of incretin hormones after glucose ingestion in humans.
Schirra J; Katschinski M; Weidmann C; Schäfer T; Wank U; Arnold R; Göke B
J Clin Invest; 1996 Jan; 97(1):92-103. PubMed ID: 8550855
[TBL] [Abstract][Full Text] [Related]
55. What do we know about the secretion and degradation of incretin hormones?
Deacon CF
Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
[TBL] [Abstract][Full Text] [Related]
56. The release of gastric inhibitory peptide, glucagon-like peptide-I, and insulin after oral glucose test in colectomized subjects.
Palnaes Hansen C; Andreasen JJ; Holst JJ
Scand J Gastroenterol; 1997 May; 32(5):473-7. PubMed ID: 9175210
[TBL] [Abstract][Full Text] [Related]
57. Sensing of L-Arginine by Gut-Expressed Calcium Sensing Receptor Stimulates Gut Satiety Hormones Cholecystokinin and Glucose-Dependent Insulinotropic Peptide Secretion in Pig Model.
Wang C; Kang C; Xian Y; Zhang M; Chen X; Pei M; Zhu W; Hang S
J Food Sci; 2018 Sep; 83(9):2394-2401. PubMed ID: 30088839
[TBL] [Abstract][Full Text] [Related]
58. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
59. Interaction of glucagon-like peptide-1(7-36) amide and gastric inhibitory polypeptide or cholecystokinin on insulin and glucagon secretion from the isolated perfused rat pancreas.
Suzuki S; Kawai K; Ohashi S; Watanabe Y; Yamashita K
Metabolism; 1992 Apr; 41(4):359-63. PubMed ID: 1556941
[TBL] [Abstract][Full Text] [Related]
60. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
